Hot Features
Prescient Therapeutics Limited, a clinical stage oncology company, develops drugs for the treatment of haematological and solid cancers in Australia. Its lead drug candidate is PTX-100, a first in class targeted therapy which can disrupt the RAS family pathway by inhibiting the prenylation action of... Prescient Therapeutics Limited, a clinical stage oncology company, develops drugs for the treatment of haematological and solid cancers in Australia. Its lead drug candidate is PTX-100, a first in class targeted therapy which can disrupt the RAS family pathway by inhibiting the prenylation action of the enzyme GGT-1. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.006 | -7.69230769231 | 0.078 | 0.081 | 0.071 | 942640 | 0.0766299 | DE |
| 4 | 0.019 | 35.8490566038 | 0.053 | 0.088 | 0.051 | 1138883 | 0.07126903 | DE |
| 12 | 0.014 | 24.1379310345 | 0.058 | 0.088 | 0.049 | 892366 | 0.06152568 | DE |
| 26 | -0.008 | -10 | 0.08 | 0.125 | 0.049 | 1418004 | 0.07559979 | DE |
| 52 | 0.025 | 53.1914893617 | 0.047 | 0.125 | 0.04 | 1368457 | 0.06316631 | DE |
| 156 | -0.012 | -14.2857142857 | 0.084 | 0.125 | 0.037 | 953600 | 0.05891678 | DE |
| 260 | -0.058 | -44.6153846154 | 0.13 | 0.305 | 0.037 | 1308196 | 0.13321221 | DE |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.